Multiple Myeloma Articles

Expert Highlights Encouraging PFS Data With Maintenance Ixazomib in Multiple Myeloma
Gareth Morgan, MD, discusses the TOURMALINE-MM3 findings in multiple myeloma and other clinical trials that are impacting the landscape for this patient population.
Treatment for Newly Diagnosed Patients Shifts Across Myeloma Spectrum
Jesus Berdeja, MD, discusses emerging standards of care in transplant-eligible and -ineligible patients with newly diagnosed multiple myeloma.
FDA Approves Split-Dosing Regimen of Daratumumab for Multiple Myeloma
The FDA has approved a split-dosing regimen of daratumumab for patients with multiple myeloma, providing physicians the option to split the first infusion of the CD38-directed monoclonal antibody over 2 consecutive days or complete in a single session.
New Paradigm Is Shaping Up for High-Risk Smoldering Myeloma
More than a dozen new treatments have boosted survival times for individuals with multiple myeloma. Now, researchers are beginning trials to investigate whether any of those treatments might improve on observation for patients with smoldering multiple myeloma who are at the highest risk of progression.
The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2019, to discuss a new drug application for selinexor in combination with dexamethasone for the treatment of patients with penta-refractory multiple myeloma.
Expert Highlights Ongoing Advances in Multiple Myeloma
Sarah Holstein, MD, PhD, highlights the vast treatment paradigm of myeloma and shared some considerations for sequencing.
Isatuximab Triplet Improves PFS in Relapsed/Refractory Myeloma
Isatuximab in combination with pomalidomide (Pomalyst) and low-dose dexamethasone was shown to prolong progression-free survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Chari Highlights Emerging Options in Heavily Pretreated Myeloma
Ajai Chari, MD, discusses novel treatment approaches for patients with heavily pretreated multiple myeloma.
Selinexor/Daratumumab Combo Shows Promise in Relapsed/Refractory Myeloma
Cristina Gasparetto, MD, discusses the combination of daratumumab, selinexor, and dexamethasone in patients with multiple myeloma who have previously received ≥3 lines of therapy, which include an immunomodulatory agent and a proteasome inhibitor.
FDA Approval Sought for Daratumumab/Rd for Frontline Transplant-Ineligible Myeloma
A supplemental Biologics License Application (sBLA) has been initiated with the FDA for daratumumab (Darzalex) for use in combination with lenalidomide (Revlimid) and dexamethasone (DRd) for the treatment of certain patients with multiple myeloma.
Publication Bottom Border
Border Publication